Evaluating the Age-Based Recommendations for Long-Term Follow-Up in Breast Cancer

被引:8
作者
Witteveen, Annemieke [1 ]
de Munck, Linda [3 ,4 ]
Groothuis-Oudshoorn, Catharina G. M. [2 ]
Sonke, Gabe S. [5 ]
Poortmans, Philip M. [6 ,7 ]
Boersma, Liesbeth J. [8 ,9 ]
Smidt, Marjolein L. [9 ,10 ]
Vliegen, Ingrid M. H. [11 ]
IJzerman, Maarten J. [2 ,12 ,13 ]
Siesling, Sabine [2 ,3 ]
机构
[1] Univ Twente, Dept Biomed Signals & Syst Personalized eHlth Tec, POB 217, NL-7500 AE Enschede, Netherlands
[2] Univ Twente, Tech Med Ctr, Dept Hlth Technol & Serv Res, Enschede, Netherlands
[3] Netherlands Comprehens Canc Org IKNL, Dept Res, Utrecht, Netherlands
[4] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands
[5] Netherlands Canc Inst NKI, Dept Med Oncol, Amsterdam, Netherlands
[6] Iridium Kankernetwerk, Antwerp, Belgium
[7] Univ Antwerp, Fac Med & Hlth Sci, Antwerp, Belgium
[8] Maastricht Univ, Dept Radiat Oncol, Med Ctr Maastro, Maastricht, Netherlands
[9] Maastricht Univ, GROW Sch Oncol & Dev Biol, Med Ctr, Maastricht, Netherlands
[10] Maastricht Univ, Dept Surg, Med Ctr, Maastricht, Netherlands
[11] Tech Univ Eindhoven, Dept Ind Engn & Innovat Sci, Eindhoven, Netherlands
[12] Univ Melbourne, Ctr Canc Res, Melbourne, Vic, Australia
[13] Univ Melbourne, Ctr Hlth Policy, Melbourne, Vic, Australia
关键词
Breast cancer; Risk-based follow-up; Locoregional recurrence; Second primary; Thresholds; CONSERVING TREATMENT; TUMOR RECURRENCE; RISK-FACTORS; WOMEN; RELAPSE; CARE; RECEPTOR; YOUNGER; IMPACT;
D O I
10.1634/theoncologist.2019-0973
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background After 5 years of annual follow-up following breast cancer, Dutch guidelines are age based: annual follow-up for women <60 years, 60-75 years biennial, and none for >75 years. We determined how the risk of recurrence corresponds to these consensus-based recommendations and to the risk of primary breast cancer in the general screening population. Subjects, Materials, and Methods Women with early-stage breast cancer in 2003/2005 were selected from the Netherlands Cancer Registry (n= 18,568). Cumulative incidence functions were estimated for follow-up years 5-10 for locoregional recurrences (LRRs) and second primary tumors (SPs). Risks were compared with the screening population without history of breast cancer. Alternative cutoffs for age were determined by log-rank tests. Results The cumulative risk for LRR/SP was lower in women <60 years (5.9%, 95% confidence interval [CI] 5.3-6.6) who are under annual follow-up than for women 60-75 (6.3%, 95% CI 5.6-7.1) receiving biennial visits. All risks were higher than the 5-year risk of a primary tumor in the screening population (ranging from 1.4% to 1.9%). Age cutoffs <50, 50-69, and > 69 revealed better risk differentiation and would provide more risk-based schedules. Still, other factors, including systemic treatments, had an even greater impact on recurrence risks. Conclusion The current consensus-based recommendations use suboptimal age cutoffs. The proposed alternative cutoffs will lead to a more balanced risk-based follow-up and thereby more efficient allocation of resources. However, more factors should be taken into account for truly individualizing follow-up based on risk for recurrence. Implications for Practice The current age-based recommendations for breast cancer follow-up after 5 years are suboptimal and do not reflect the actual risk of recurrent disease. This results in situations in which women with higher risks actually receive less follow-up than those with a lower risk of recurrence. Alternative cutoffs could be a start toward risk-based follow-up and thereby more efficient allocation of resources. However, age, or any single risk factor, is not able to capture the risk differences and therefore is not sufficient for determining follow-up. More risk factors should be taken into account for truly individualizing follow-up based on the risk for recurrence.
引用
收藏
页码:E1330 / E1338
页数:9
相关论文
共 43 条
  • [1] Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
  • [2] Allen Alison, 2002, Eur J Oncol Nurs, V6, P155, DOI 10.1054/ejon.2002.0175
  • [3] Competing risks in epidemiology: possibilities and pitfalls
    Andersen, Per Kragh
    Geskus, Ronald B.
    de Witte, Theo
    Putter, Hein
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2012, 41 (03) : 861 - 870
  • [4] Australia Cancer, 2011, REC FOLL UP WOM EARL
  • [5] Variation of breast cancer risk among BRCA1/2 carriers
    Begg, Colin B.
    Haile, Robert W.
    Borg, Ake
    Malone, Kathleen E.
    Concannon, Patrick
    Thomas, Duncan C.
    Langholz, Bryan
    Bernstein, Leslie
    Olsen, Jorgen H.
    Lynch, Charles F.
    Anton-Culver, Hoda
    Capanu, Marinela
    Liang, Xiaolin
    Hummer, Amanda J.
    Sima, Cami
    Bernstein, Jonine L.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (02): : 194 - 201
  • [6] Combining Individual-Level Discrete Choice Experiment Estimates and Costs to Inform Health Care Management Decisions about Customized Care: The Case of Follow-Up Strategies after Breast Cancer Treatment
    Benning, Tim M.
    Kimman, Merel L.
    Dirksen, Carmen D.
    Boersma, Liesbeth J.
    Dellaert, Benedict G. C.
    [J]. VALUE IN HEALTH, 2012, 15 (05) : 680 - 689
  • [7] Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery
    Benson, John R.
    Wishart, Gordon C.
    [J]. LANCET ONCOLOGY, 2013, 14 (09) : E348 - E357
  • [8] The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone
    Campbell, Esther J.
    Tesson, Mathias
    Doogan, Flora
    Mohammed, Zahra M. A.
    Mallon, Elizabeth
    Edwards, Joanne
    [J]. BRITISH JOURNAL OF CANCER, 2016, 115 (08) : 967 - 973
  • [9] Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years
    Cortesi, Laura
    Marcheselli, Luigi
    Guarneri, Valentina
    Cirilli, Claudia
    Braghiroli, Barbara
    Toss, Angela
    Sant, Milena
    Ficarra, Guido
    Conte, Pier Franco
    Federico, Massimo
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (02) : E58 - E65
  • [10] Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
    Davies, C.
    Godwin, J.
    Gray, R.
    Clarke, M.
    Darby, S.
    McGale, P.
    Wang, Y. C.
    Peto, R.
    Pan, H. C.
    Cutter, D.
    Taylor, C.
    Ingle, J.
    [J]. LANCET, 2011, 378 (9793) : 771 - 784